Connecticut Cannabis Program: Laws, Regulations & Market Overview

Executive Summary

Connecticut's adult-use cannabis program underwent two major regulatory changes on October 1, 2026, eliminating THC-based taxation and removing the 70% THC concentration cap on cannabis concentrates. These reforms mark a significant maturation of Connecticut's recreational marijuana market, which launched in January 2023 following voter approval of legalization in 2021. The elimination of THC-based taxes simplifies the state's cannabis tax structure, moving to a straightforward retail excise tax model that reduces administrative burden for operators and provides pricing predictability for consumers. Simultaneously, the removal of the 70% THC cap on concentrates expands product availability and aligns Connecticut with neighboring states like Massachusetts and New York that impose no such potency restrictions. These changes reflect the Connecticut Department of Consumer Protection's ongoing refinement of regulations based on nearly four years of operational data from the adult-use market. Industry stakeholders view the reforms as competitive necessities that will help Connecticut retailers compete with illicit markets and cross-border shopping while generating sustained tax revenue for the state's Social Equity Council and other programs funded by cannabis sales.

Why This Matters

These regulatory changes affect Connecticut's 600,000+ estimated cannabis consumers, 35+ licensed adult-use retailers, dozens of cultivators and product manufacturers, and the state's $150+ million annual cannabis tax revenue stream. The elimination of THC-based taxation removes a complex compliance burden that required laboratory testing and potency-based calculations for every product sold. This system created administrative costs for retailers, testing laboratories, and state regulators while providing minimal policy benefit. The shift to a simpler retail excise tax model reduces operational friction and allows the Department of Consumer Protection to focus enforcement resources on more critical public health and safety priorities. For consumers, the removal of the 70% THC concentrate cap expands access to high-potency products including live resin, rosin, distillates, and crystalline concentrates that previously required out-of-state purchases. Connecticut's concentrate cap was among the most restrictive in the nation, with only Vermont imposing a similar 60% limit. Medical patients who rely on high-potency concentrates for symptom management particularly benefit from expanded product selection, though the changes apply to both adult-use and medical programs. The reforms carry significant market implications for Connecticut's multi-state operators including Curaleaf, Trulieve, and Acreage Holdings, which operate multiple dispensaries across the state. These companies invested heavily in Connecticut licenses and infrastructure based on population density and proximity to New York City markets. Regulatory modernization improves return-on-investment projections and competitive positioning against Massachusetts retailers that have captured Connecticut border-county customers. Connecticut's Social Equity Council, which receives 25% of cannabis tax revenue to fund business incubators, workforce development, and community reinvestment in areas disproportionately affected by prohibition enforcement, depends on sustained market growth. Regulatory reforms that reduce illicit market competition and cross-border shopping directly impact funding available for equity programs.

Background and History: Connecticut's Path to Legalization

Connecticut's journey from prohibition to regulated adult-use cannabis spanned more than a decade, beginning with medical marijuana authorization in 2012 and culminating in recreational legalization in 2021.

Medical Marijuana Foundation (2012-2021)

Connecticut established its medical cannabis program through Public Act 12-55, signed by Governor Dannel Malloy on June 1, 2012. The legislation created a tightly regulated dispensary system limited to patients with specific qualifying conditions including cancer, glaucoma, HIV/AIDS, Parkinson's disease, multiple sclerosis, and epilepsy. The Department of Consumer Protection received regulatory authority over licensing, testing, and compliance. The first medical dispensaries opened in August 2014 after a two-year implementation period. Connecticut initially licensed four vertically integrated operators, each permitted to operate one dispensary and one cultivation facility. The program expanded gradually, reaching nine licensed producers and 18 dispensaries by 2020. Medical cannabis sales totaled approximately $25 million in 2015, growing to $35 million in 2019 as the patient registry expanded to 50,000 registered individuals. In 2020, the Connecticut General Assembly expanded qualifying conditions to include post-traumatic stress disorder, anxiety disorders, and chronic pain, broadening patient eligibility significantly. The Department of Consumer Protection also authorized home cultivation for medical patients, permitting up to three mature and three immature plants per patient.

Legalization Debate and Passage (2019-2021)

Governor Ned Lamont made adult-use legalization a legislative priority beginning in 2019, citing tax revenue potential and social justice imperatives. His initial proposal in 2019 failed to advance through the General Assembly amid concerns about impaired driving, youth access, and implementation timelines. The 2020 legislative session was disrupted by the COVID-19 pandemic, delaying legalization efforts. However, the fiscal crisis created by pandemic-related revenue shortfalls increased legislative interest in cannabis tax revenue as a budget solution. In 2021, Governor Lamont and legislative leaders negotiated a comprehensive legalization framework. The Connecticut General Assembly passed Public Act 21-1 on June 16, 2021, with bipartisan support. The legislation authorized adult-use possession, cultivation, and commercial sales while establishing a detailed regulatory structure and social equity provisions.

Regulatory Implementation (2021-2022)

Public Act 21-1 legalized possession of up to 1.5 ounces of cannabis flower and 5 ounces in a locked container at home for adults 21 and older, effective July 1, 2021. Home cultivation remained prohibited for adult-use consumers, permitted only for medical patients. The Department of Consumer Protection began accepting adult-use license applications in April 2022. The agency created multiple license categories including cultivators, product manufacturers, retailers, hybrid retailers (medical dispensaries adding adult-use sales), micro-cultivators, and delivery services. The licensing framework prioritized social equity applicants through a point-based scoring system that awarded advantages to Connecticut residents, minority-owned businesses, and applicants from communities disproportionately affected by cannabis prohibition. Connecticut established a Social Equity Council within the Department of Consumer Protection, funded by 25% of cannabis tax revenue. The Council's mandate includes providing technical assistance, capital access, and workforce training to equity applicants and funding community reinvestment programs in designated disproportionately impacted areas.

Market Launch and Early Operations (2023-2024)

Connecticut's first adult-use sales occurred on January 10, 2023, at seven hybrid retailers—existing medical dispensaries that received adult-use authorization. Initial product availability was limited due to cultivation capacity constraints, with retailers implementing purchase limits and experiencing frequent stock shortages. First-month sales totaled $6.8 million across the seven initial retailers. The Department of Consumer Protection approved additional retail licenses throughout 2023, expanding the market to 25 operating dispensaries by December 2023. Cultivation capacity increased as new growers came online and existing medical producers expanded operations. The state's initial tax structure included a 6.35% standard sales tax plus a retail excise tax calculated based on THC content: $0.00625 per milligram for flower, $0.0275 per milligram for edibles, and $0.0275 per milligram for other products. This THC-based taxation model required extensive laboratory testing and complex point-of-sale calculations. Connecticut also implemented a 70% THC concentration cap on all cannabis concentrates, including waxes, shatters, oils, and distillates. The Department of Consumer Protection justified the cap as a public health measure to limit youth access to high-potency products, though no evidence demonstrated that potency caps reduced underage consumption.

Market Maturation and Regulatory Evolution (2024-2026)

By 2024, Connecticut's cannabis market had matured significantly. Annual sales reached approximately $150 million, generating $25-30 million in state tax revenue. The retailer count expanded to 35 licensed dispensaries, with additional licenses pending. Cultivation capacity stabilized, eliminating the supply shortages that characterized the first year of operations. However, operators and regulators identified implementation challenges. The THC-based tax structure created administrative complexity, requiring continuous laboratory testing, frequent price adjustments as potency varied between batches, and sophisticated point-of-sale systems to calculate taxes accurately. Retailers reported that the system confused consumers and created compliance risks. The 70% THC cap on concentrates proved increasingly controversial. Medical patients and adult-use consumers sought higher-potency products available in neighboring states. Industry representatives argued that the cap lacked scientific justification and drove consumers to Massachusetts dispensaries or illicit markets. Data from the Department of Consumer Protection showed that concentrate sales represented only 12% of total cannabis sales in Connecticut compared to 25-30% in states without potency restrictions. In response to stakeholder feedback, the Department of Consumer Protection initiated a regulatory review in late 2024. The agency held public hearings in Hartford, New Haven, and Stamford, receiving testimony from retailers, cultivators, medical patients, public health advocates, and municipal officials. The review process examined tax structure alternatives, potency regulations, and other operational issues. In June 2026, the Department of Consumer Protection published proposed regulatory amendments eliminating THC-based taxation in favor of a flat retail excise tax and removing the 70% concentrate cap. The agency accepted public comments through August 2026 and finalized the regulations in September 2026, with an effective date of October 1, 2026.

Key Players in Connecticut's Cannabis Program

Department of Consumer Protection

The Department of Consumer Protection serves as Connecticut's primary cannabis regulatory authority, overseeing licensing, compliance, testing standards, and enforcement for both medical and adult-use programs. Commissioner Michelle Seagull, appointed by Governor Lamont in 2023, led the regulatory review process that resulted in the October 2026 reforms. The department's Drug Control Division manages day-to-day cannabis operations, including license application processing, facility inspections, and complaint investigations.

Social Equity Council

Connecticut's Social Equity Council operates within the Department of Consumer Protection with a mandate to promote diversity in cannabis business ownership and reinvest tax revenue in communities disproportionately affected by prohibition enforcement. The Council receives 25% of cannabis tax revenue and administers grant programs, business accelerators, and workforce development initiatives. The Council prioritizes applicants from designated disproportionately impacted areas—census tracts with above-average rates of cannabis-related arrests, unemployment, and poverty.

Major Multi-State Operators

Curaleaf operates four dispensaries in Connecticut, including locations in Hartford, Stamford, Milford, and Groton. The company also operates cultivation and processing facilities in Simsbury. Curaleaf entered Connecticut through its 2021 acquisition of Alternative Compassion Services, one of the state's original medical marijuana operators. Trulieve operates three Connecticut dispensaries in Norwalk, Westport, and Uncasville following its 2023 acquisition of The Botanist dispensary chain. The company cultivates cannabis at a facility in Watertown. Acreage Holdings operates dispensaries in Newington and Bridgeport under The Botanist brand. The company's Connecticut cultivation facility in Berlin supplies its retail locations and wholesale customers.

Connecticut Cannabis Industry Association

The Connecticut Cannabis Industry Association represents licensed operators, advocating for regulatory reforms and industry interests. The association supported the elimination of THC-based taxation and concentrate caps, arguing that these policies created competitive disadvantages relative to neighboring states and strengthened illicit markets.

Medical Patient Advocates

Connecticut medical cannabis patients, organized through groups including the Connecticut chapter of NORML and Americans for Safe Access, consistently advocated for removing the 70% THC concentrate cap. Patient testimony during the 2024-2026 regulatory review emphasized that high-potency concentrates provide effective symptom management for chronic pain, epilepsy, and other qualifying conditions with smaller doses and reduced inhalation volume compared to flower consumption.

Legal and Regulatory Framework

Connecticut's cannabis program operates under Public Act 21-1, codified in Connecticut General Statutes Title 21a, Chapter 420f, with detailed regulations in Sections 21a-420 through 21a-420gg. The legislation establishes separate but parallel regulatory frameworks for medical and adult-use cannabis. Both programs operate under Department of Consumer Protection oversight, with shared testing standards, security requirements, and product safety regulations.

Possession and Cultivation Limits

Adults 21 and older may possess up to 1.5 ounces of cannabis flower outside the home and up to 5 ounces in a locked container at a primary residence. Public consumption remains prohibited, with violations subject to civil penalties ranging from $150 for a first offense to $500 for subsequent offenses. Home cultivation is permitted only for registered medical patients, who may grow up to three mature and three immature plants in an enclosed, locked space. Adult-use home cultivation remains prohibited under Connecticut law, distinguishing the state from neighboring Massachusetts, Maine, and Vermont, which permit limited home growing for all adults.

Licensing Categories and Requirements

Connecticut issues multiple cannabis license types. Cultivator licenses authorize indoor or outdoor cannabis growing, with canopy size tiers determining license fees and production capacity. Product manufacturer licenses permit extraction, infusion, and processing of cannabis into edibles, concentrates, topicals, and other derivative products. Retailer licenses authorize dispensary operations, while hybrid retailer licenses permit existing medical dispensaries to add adult-use sales. The Department of Consumer Protection also created micro-cultivator and delivery service licenses to promote small business participation and expand access. Micro-cultivators may grow cannabis in facilities up to 10,000 square feet and sell directly to retailers or consumers. Delivery services may transport and sell cannabis products to consumers at residential addresses. All license applicants must demonstrate financial capacity, pass background checks, and meet security and operational standards. Social equity applicants receive scoring advantages and access to technical assistance and capital programs administered by the Social Equity Council.

Taxation Structure

Prior to October 1, 2026, Connecticut imposed a complex THC-based excise tax: $0.00625 per milligram of THC for flower, $0.0275 per milligram for edibles, and $0.0275 per milligram for other products. This structure required laboratory testing of every product batch and point-of-sale calculations based on package potency. The October 2026 reforms replaced THC-based taxation with a flat retail excise tax structure. The new system imposes a percentage-based excise tax on retail sales, calculated on the pre-tax sale price. The standard 6.35% Connecticut sales tax continues to apply to all cannabis purchases. Revenue from cannabis taxes flows to multiple designated funds. The General Fund receives 50% of cannabis tax revenue for general state expenses. The Social Equity Council receives 25% for equity programs and community reinvestment. Municipal governments receive 15% distributed based on the number of licensed cannabis businesses operating within their jurisdictions. The remaining 10% funds substance abuse prevention and treatment programs administered by the Department of Mental Health and Addiction Services.

Product Standards and Testing

All cannabis products sold in Connecticut must undergo testing by licensed laboratories for potency, pesticides, heavy metals, microbial contaminants, and residual solvents. The Department of Consumer Protection maintains a list of approved testing laboratories and publishes testing standards in its regulations. Prior to October 2026, Connecticut prohibited the sale of cannabis concentrates exceeding 70% THC by weight. This restriction applied to all concentrate forms including waxes, shatters, oils, distillates, and crystalline products. The October 2026 regulatory amendments eliminated this potency cap, permitting concentrates of any THC concentration provided they meet testing and labeling requirements. Connecticut requires child-resistant packaging for all cannabis products and prohibits packaging that appeals to minors. Edible products must be individually wrapped in servings not exceeding 5 milligrams of THC, with packages limited to 100 milligrams total THC content.

Federal Law Conflicts

Connecticut's cannabis program operates in direct conflict with federal law. The Controlled Substances Act, 21 U.S.C. § 812, classifies cannabis as a Schedule I controlled substance, prohibiting its manufacture, distribution, and possession. However, federal enforcement priorities since 2013 have generally avoided interference with state-compliant cannabis operations, a policy formalized in the 2013 Cole Memorandum and continued through subsequent administrations despite the memorandum's 2018 rescission. Connecticut cannabis businesses face federal tax consequences under Internal Revenue Code Section 280E, which prohibits business expense deductions for enterprises trafficking in Schedule I or II controlled substances. This provision results in effective tax rates of 60-80% for cannabis operators, significantly exceeding rates for legal businesses in other industries.

Market and Business Implications

The elimination of THC-based taxation and concentrate caps positions Connecticut's cannabis market for accelerated growth, with industry analysts projecting 15-20% annual sales increases through 2028.

Operational Efficiency Gains

The shift from THC-based to retail excise taxation reduces compliance costs for retailers, cultivators, and testing laboratories. Under the previous system, retailers required sophisticated point-of-sale systems to calculate taxes based on product potency, which varied between batches even for the same strain. Price labels required frequent updates as new batches with different potency levels arrived. The flat retail excise tax eliminates these complications, allowing standard percentage-based calculations identical to sales tax. Testing laboratories benefit from reduced testing demand. While potency testing remains required for product labeling, the elimination of tax calculations based on precise THC milligram content reduces the frequency and precision requirements for testing. Laboratories can redirect resources toward more critical safety testing for contaminants and adulterants.

Product Mix Expansion

The removal of the 70% THC concentrate cap enables retailers to stock high-potency products including THCA crystalline (approaching 100% purity), live resin concentrates (typically 75-90% THC), and distillate cartridges (typically 80-95% THC). These products command premium prices and higher profit margins compared to flower, improving retailer economics. Concentrate sales in states without potency restrictions typically represent 25-30% of total cannabis revenue, compared to Connecticut's pre-reform 12% concentrate share. Industry analysts project that Connecticut concentrate sales will increase to 20-25% of total market revenue within 12 months of the cap removal, adding $30-40 million in annual sales. Product manufacturers gain flexibility to develop new concentrate-based products including high-potency vape cartridges, dabbable extracts, and infused pre-rolls that previously exceeded the 70% limit. This innovation potential attracts capital investment and positions Connecticut manufacturers to compete with Massachusetts and New York producers.

Competitive Positioning

Connecticut's regulatory reforms address competitive disadvantages relative to neighboring states. Massachusetts, which borders Connecticut to the north, operates a mature cannabis market with no concentrate potency caps and a simpler tax structure. Data from the Massachusetts Cannabis Control Commission shows that approximately 15-20% of Massachusetts dispensary customers provide Connecticut addresses, representing $50-75 million in annual cross-border sales. The elimination of Connecticut's concentrate cap and tax complexity reduces incentives for cross-border shopping. Retailers in Hartford, New Haven, and Fairfield counties—which experienced the highest rates of customer loss to Massachusetts—anticipate immediate market share gains. New York's adult-use market, which launched in December 2022, presents both competition and opportunity for Connecticut operators. New York's slower licensing pace and limited dispensary count in Westchester County and New York City create opportunities for Connecticut retailers near the state border. However, as New York's market matures, Connecticut must maintain competitive regulations and pricing to retain customers.

Investment and Expansion

Regulatory modernization improves Connecticut's attractiveness to cannabis investors and multi-state operators evaluating expansion opportunities. Curaleaf, Trulieve, and other MSOs operating in Connecticut have announced plans to expand cultivation capacity and open additional dispensaries in response to the regulatory reforms. Connecticut's population density, proximity to New York City markets, and relatively high median household income make the state attractive for cannabis investment. However, regulatory complexity and restrictive product rules previously limited return-on-investment projections. The October 2026 reforms remove these barriers, positioning Connecticut as a priority market for capital deployment.

Social Equity Impact

The Social Equity Council's funding depends on sustained cannabis tax revenue growth. The elimination of THC-based taxation simplifies the tax structure but does not reduce tax rates, maintaining revenue projections. Increased sales driven by expanded product availability and reduced cross-border shopping will generate additional revenue for equity programs. The Council operates business accelerators in Hartford, New Haven, and Bridgeport, providing technical assistance, mentorship, and capital access to equity applicants. As of September 2026, the Council had distributed $8.5 million in grants and low-interest loans to 47 equity applicants, supporting 12 operational dispensaries and 8 cultivation facilities owned by social equity licensees. Regulatory reforms that strengthen the legal market and increase overall sales create more opportunities for equity operators to achieve profitability and scale their businesses. However, equity advocates note that federal tax burdens under Section 280E and limited access to banking services continue to disadvantage small operators regardless of state-level reforms.

What Experts Say

Industry stakeholders, public health researchers, and policy analysts offered varied perspectives on Connecticut's regulatory reforms during the 2024-2026 review process. According to testimony submitted to the Department of Consumer Protection, the Connecticut Cannabis Industry Association characterized THC-based taxation as administratively burdensome and economically inefficient. The association's written comments noted that the tax structure required continuous laboratory testing, created price volatility, and confused consumers who struggled to understand why identical products carried different prices based on potency variations. Medical cannabis patients testified that the 70% THC concentrate cap forced them to purchase products in Massachusetts or rely on illicit sources. Patient advocates emphasized that high-potency concentrates allow effective symptom management with smaller doses, reducing inhalation volume and associated respiratory risks compared to smoking flower. Public health researchers at the Yale School of Public Health submitted comments acknowledging that evidence supporting potency caps as an effective public health intervention remains limited. The researchers noted that no peer-reviewed studies demonstrate that potency restrictions reduce youth consumption or prevent cannabis use disorder. However, the researchers recommended enhanced consumer education about potency and dosing to accompany the cap removal. Municipal officials from Hartford, New Haven, and Stamford supported the regulatory reforms, emphasizing that competitive disadvantages relative to Massachusetts retailers reduced local tax revenue and strengthened illicit markets. Hartford Mayor Luke Bronin stated in public hearing testimony that regulatory modernization would help legal retailers compete effectively and generate sustained municipal revenue from cannabis business operations. Cannabis testing laboratory operators testified that THC-based taxation created unnecessary testing demand and diverted resources from critical safety testing. Laboratory representatives noted that potency testing for tax purposes required precision levels exceeding those needed for consumer labeling, increasing costs without corresponding public health benefits. Opponents of the concentrate cap removal, including some addiction medicine specialists, expressed concerns about high-potency product availability and potential increases in cannabis use disorder. However, these concerns were not supported by data from states without potency caps, which have not experienced measurable increases in problem use or emergency department visits related to concentrate consumption.

What's Next: Implementation and Future Reforms

The October 1, 2026 implementation of Connecticut's regulatory reforms marks the beginning of a transition period as retailers, cultivators, and regulators adapt to the new framework.

Near-Term Implementation (October 2026 - March 2027)

Retailers are updating point-of-sale systems to reflect the new flat retail excise tax structure, eliminating THC-based calculations. The Department of Consumer Protection is providing technical guidance and compliance assistance during the transition period. Product manufacturers are developing and submitting new high-potency concentrate products for testing and approval. The department anticipates a surge in product registration applications as manufacturers introduce concentrates exceeding the previous 70% THC limit. Initial high-potency products are expected to reach dispensary shelves by November 2026. The Department of Consumer Protection will monitor market impacts, tracking concentrate sales volumes, pricing trends, and consumer purchasing patterns. The agency committed to publishing quarterly market data reports to assess the reforms' effects on sales, tax revenue, and cross-border shopping patterns.

Potential Future Reforms

Industry stakeholders continue to advocate for adult-use home cultivation authorization, which remains prohibited under current Connecticut law. Legalization advocates argue that home growing reduces illicit market demand and provides access for consumers in areas underserved by licensed retailers. However, law enforcement organizations and some municipal officials oppose home cultivation expansion, citing enforcement challenges and neighborhood concerns. The Connecticut General Assembly may consider additional reforms during the 2027 legislative session, including expanded retail licensing, delivery service regulations, and consumption lounge authorization. Governor Lamont has expressed openness to consumption lounges—licensed establishments where adults may consume cannabis on-site—as a regulated alternative to public consumption. Federal cannabis policy developments will significantly impact Connecticut's program. If Congress passes legislation removing cannabis from Schedule I of the Controlled Substances Act or enacting the SAFE Banking Act to provide financial services access, Connecticut operators would benefit from reduced tax burdens under Section 280E and expanded access to traditional banking and capital markets. The Department of Consumer Protection's regulatory review process continues, with the agency soliciting ongoing stakeholder feedback on testing standards, packaging requirements, and licensing procedures. Future reforms may address laboratory accreditation standards, pesticide use regulations, and environmental sustainability requirements for cultivation operations.

Market Projections

Industry analysts project that Connecticut's cannabis market will reach $200-225 million in annual sales by the end of 2027, driven by expanded product availability, reduced cross-border shopping, and continued retail license issuance. The state's tax revenue from cannabis is projected to reach $35-40 million annually by 2028, providing sustained funding for social equity programs and municipal revenue sharing. The Social Equity Council plans to expand its business accelerator programs to additional cities and increase grant funding for equity applicants. The Council's 2027 strategic plan includes workforce development partnerships with community colleges and technical schools to create cannabis industry career pathways for residents of disproportionately impacted areas.

Further Reading and Primary Sources

• Connecticut General Statutes Title 21a, Chapter 420f (Cannabis): https://www.cga.ct.gov/current/pub/chap_420f.htm
• Public Act 21-1: An Act Concerning Responsible and Equitable Regulation of Adult-Use Cannabis: https://www.cga.ct.gov/2021/act/PA/PDF/2021PA-00001-R00HB-06377-PA.PDF
• Connecticut Department of Consumer Protection, Drug Control Division: https://portal.ct.gov/DCP/Drug-Control-Division/Drug-Control
• Connecticut Social Equity Council: https://portal.ct.gov/DCP/Social-Equity-Council
• Connecticut Cannabis Sales and Tax Revenue Data (Department of Revenue Services): https://portal.ct.gov/DRS/DRS-Reports/Statistical-Reports
• Connecticut Regulations of Connecticut State Agencies, Sections 21a-420-1 through 21a-420-14: https://eregulations.ct.gov/eRegsPortal/Browse/RCSA
• Controlled Substances Act, 21 U.S.C. § 812: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13-subchapI-partB-sec812.pdf
• Internal Revenue Code Section 280E: https://www.law.cornell.edu/uscode/text/26/280E
• Massachusetts Cannabis Control Commission Market Data: https://masscannabiscontrol.com/open-data/
• Yale School of Public Health Cannabis Research Initiative: https://publichealth.yale.edu/